2b trial variation-safety profile assessment, page-2

'no longer eligible for study participation due to disease progression'

Perhaps the parameters of dosing/conditions for the original trial were sought to be expanded.

Also dont forget we are dealing with a spectrum of the condition, i dont know the original inclusion criteria- but if some subjects were included in later stages of the disease, one could understand possible alteration of medication delivery for the patients wellbeing. IMO this perhaps shows we have displayed some efficacy, otherwise why set up a sub trial? must have had at least some effect no? And what of the other subjects? no progression noted?

just thoughts,